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Efforts to develop a vaccine to prevent infection of human immunodeficiency virus (HIV) have focused on the induction of
neutralizing antibodies. In our previous study, we reported that chimeric gag–env virus-like particles (VLPs) induce neutral-
izing antibodies which block HIV infection. In addition to the neutralizing antibodies, the cytotoxic T-lymphocyte (CTL)
response is considered to be another major immune defense mechanism required for recovery from many different viral
infections. In the present study, we have constructed chimeric fusion proteins using HIV-2 gag precursor protein with (1) four
neutralizing epitopes from HIV-1 gp160; (2) three tandem copies of consensus V3 domain, which have been derived from 245
different isolates of HIV-1 and carries both the principal neutralizing determinant (PND) and CTL epitopes; and (3) V3 domains
from HIV-1IIIB, HIV-1MN, HIV-1RF, and HIV-1SF2. These chimeric fusion proteins were expressed in a large quantity within
insect cells, and released as VLPs into the cell culture medium. The purified gag–env VLPs from all three constructs appear
to be spherical particles similar to immature HIV but slightly larger than the gag VLPs. Immunoprecipitation analysis showed
that the chimeric proteins were recognized not only by HIV-1 positive patient sera, but also by monoclonal and polyclonal
antisera raised against V3 peptides of HIV-1IIIB, HIV-1MN, HIV-1RF, and the gp120 antiserum against HIV-1SF2. Balb/C mice
immunized with these chimeric VLPs successfully induced CTL activity against V3 peptide-stimulated target cells. In addition,
a high degree of cross-reactivity was observed among the four different strains of HIV-1 V3 domain, indicating that the
tandem multiple consensus V3 peptide sequence carried by HIV-2 gag can be used as a potential HIV vaccine against various
HIVs. © 1998 Academic Press
INTRODUCTION
The development of an AIDS vaccine to prevent HIV
infection has been focused on the induction of both
humoral and cell mediated immune responses. The neu-
tralizing antibodies eliminate extracellular viruses,
whereas the viruses primarily spread by virus-infected
cells which can be destroyed by the viral-specific cyto-
toxic T lymphocytes (CTLs)(Townsend et al., 1986; Rouse
et al., 1988; Klavinskis et al., 1989). The CTLs that are
capable of lysing target cells expressing HIV proteins
have been detected in HIV-infected patients, and these
HIV-specific CTLs can inhibit HIV replication in periph-
eral blood lymphocytes (Tsubota et al., 1989). Accord-
ingly, CTLs appear to play a critical role in the control of
HIV infection.
HIV-1 V3 domain has been shown to be an immuno-
dominant site of principal neutralizing determinant (PND)
and contains the T-cell epitopes of the HIV env glycopro-
tein. Therefore, the V3 region contains an important se-
quence for a vaccine formulation (Berzofsky et al., 1991;
Luo et al., 1992; Casement et al., 1995). However, neu-
tralizing antibodies found in HIV-1-infected individuals, or
induced by immunizing animals with gag-V3 chimeric
proteins derived from a single strain of HIV-1, or induced
by candidate HIV-1 vaccines based on gp120 have been
predominantly type specific, thus indicating their limited
value as an AIDS vaccine (Goudsmit et al., 1988; Myers
1989). The induction of a broadly reactive immunity
against HIV has been impaired by the extent of sequence
variations exhibited by variants of the HIV-1 isolate. One
particularly disturbing finding is that there is a high
degree of antigenic variation in gp160, showing at least
25% of the amino acids differ. The V3 domain is one of
the more variable regions of gp120 and differs by as
much as 50% among HIV-1 isolates (Nara et al., 1988).
In the previous study, we introduced neutralization
epitopes from gp120 into the carrier protein HIV-2 gag,
which is an effective vector for the delivery and expres-
sion of foreign genes in a baculovirus system, and pre-
sented the antigen as a polyvalent particulate structure
(Luo et al., 1992). In the present study, we have also
employed the HIV-2 gag as carrier and constructed chi-
meric genes by coupling the HIV-2 gag gene with four
different epitopes from HIV-1 gp160, with three tandem
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copies of consensus V3 loop sequence (V3CS) from 245
isolates of HIV-1 or with multiple V3 loop sequences from
IIIB, MN, SF2, and RF strains of HIV-1. It has been dem-
onstrated that subunit vaccines containing multiple cop-
ies of Vp1 protein of foot-and-mouth disease virus
(Brown et al., 1988) and of gD protein of herpes simplex
virus (Prevec and Rosenthal, McMaster University, pers.
commun.) showed strong immune responses.
Large quantities of gag–env fusion proteins have been
produced in insect cells using a baculovirus expression
system and used to evaluate the ability to induce both
humoral and cellular immune responses.
RESULTS
Construction and expression of chimeric proteins
In an attempt to produce gag–env chimeric proteins for
eliciting both humoral and cell mediated immune re-
sponses, a subclone of the truncated HIV-2gag425 gene
in the pUC19 plasmid was used as a carrier of the
multiple V3 genes to form gag–env chimeric proteins.
The basic strategy used to construct plasmids for ex-
pression of gag–V3 fusion proteins is illustrated in Fig. 1
and described under Materials and Methods. The four
different oligonucleotide sequences from fragments of
HIV-1 gp160, which were postulated to be antigenic
epitopes (Broliden et al., 1992), the three tandem copies
of the consensus principal neutralizing determinant
(PND), which were based on the V3 loop consensus
sequence obtained from 245 HIV-1 isolates (LaRosa et
al., 1990), and multiples PNDs from four different iso-
lates, HIV-1IIIB, HIV-1MN, HIV-1RF, and HIV-1SF2 (Taka-
hashi et al., 1992), were synthesized individually as indi-
cated in Fig. 1 and fused directly onto the C-terminal BglII
site of pUC19-GAG of HIV-2. The resulting plasmids were
digested with the restriction enzyme BamHI and sub-
cloned into the baculovirus transfer vector pBacPAK1.
Following cotransfection with wild type BacPAK6 DNA,
three corresponding recombinant baculoviruses were
generated and designated as Ac–gag–V3A, Ac–gag–
V3B, and Ac–gag–V3C. The ability of each of the recom-
binant baculoviruses to direct the synthesis of the
gag–V3 fusion protein was tested in SF21 cells. The
whole cell lysates were prepared at 3 days (postinfec-
tion) and analyzed by SDS–PAGE and Western blot. By
Coomassie blue staining of proteins from cell lysates, we
FIG. 1. Schematic representation of three chimeric gag–env genes containing multiple neutralizing epitopes of HIV-1. The three sets of synthetic
BglII-digested DNA fragments, which contain four different neutralizing epitopes of HIV-1 gp160, two from gp120 and two from gp41 (A), three tandem
copies of consensus V3 sequence obtained from 245 different HIV-1 isolates (B), and multiple V3 sequences from HIV-1IIIB, HIV-1MN, HIV-1RF, and
HIV-1SF2 (C) were phosphorylated and inserted into the BglII site of the C-terminus of truncated HIV-2 gag gene, which is just in front of the stop codon
TAA of gag gene (Luo et al., 1990, 1992). The synthetic amino acid sequences and the order of the multiple neutralizing epitopes are indicated.
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observed both gag protein alone and chimeric gag pro-
teins produced by recombinant baculoviruses AcNPV-
HIV-2gag (Luo et al., 1990), Ac–gag–V3A, Ac–gag–V3B,
and Ac–gag–V3C (Fig. 2A, lanes, 1, 2, 3, and 4) but were
not present in those of mock or wild type baculovirus-
infected cells. Since the original HIV-2gag protein has 94
amino acids deleted from the C-terminus (Luo et al.,
1990), an insertion of multiple antigenic epitopes of HIV-1
gp160 (60 amino acids), three tandem copies of consen-
sus V3 sequence (54 amino acids), or multiple V3 se-
quence (60 amino acids) from four different isolates of
HIV-1 into the C-terminus of gag gene would be expected
to produce a protein of approximately 54 kDa for gag–
V3A and gag–V3C and approximately 53 kDa for gag–
V3B. As shown in Fig. 2A, strongly stained protein band
migration at either 54 or 53 kDa were observed in the
lysates of SF21 cells infected with Ac–gag–V3A (lane 2)
and Ac–gag–V3B (lane 3). However, the fusion protein
gag–V3C expressed by Ac–gag–V3C differed slightly in
its mobility from gag–V3A, although the same size V3
sequences were added in both constructs (lane 4). This
accelerated migration could be due to the different con-
formation of chimeric protein when V3A and V3C were
fused with gag. An alternative explanation is the charge
differences between the amino acids in V3A and V3C. We
have observed this kind of variation in other proteins
although we have used SDS in the gel (unpublished
observation). Western blot analysis further revealed that
both 54 and 53-kDa fusion proteins were recognized by
pooled HIV-1 positive human sera. No specific reaction
was observed with mock and wild type baculovirus-
infected cells (Fig. 2B).
The assembly of gag–env chimeric protein into
spherical virus-like particles
We next asked whether the chimeric gag–env proteins
were able to assemble virus-like particles (VLPs) and
secreted into the cell culture media. To this end, each of
the three recombinant baculovirus-infected cell culture
supernatants, including AcNPV-HIV-2gag as positive
control, were harvested at 2 days p.i. before significant
cell lysis had occurred. After ultracentrifugation of cul-
ture supernatants, the pellet was resuspended and lay-
ered on a 20–60% discontinuous sucrose gradient as
described previously (Luo et al., 1990, 1992). We found
that all of the three recombinant baculoviruses, Ac–gag–
V3A, Ac–gag–V3B, and Ac–gag–V3C, produced sedi-
mentable chimeric virus-like particles, as did the original
gag protein alone. Figure 2C shows the purified HIV-
2gag particles (lane 1), chimeric particles gag–V3A (lane
2), gag–V3B (lane 3), and gag–V3C (lane 4) analyzed on
SDS–PAGE and visualized by Coomassie blue staining.
The size of the major fusion protein is identical to that of
the fusion protein found in cell lysate (Fig. 2A) and further
confirmed by Western blot (data not shown). These re-
sults demonstrated that the fusion proteins had been
packaged into VLPs.
To analyze the morphology of the chimeric gag–env
VLPs, the sucrose gradient purified chimeric VLPs were
examined by transmission electron microscopy (EM) us-
ing uranyl acetate staining. The electron micrograph of
chimeric VLPs and the HIV-2gag particles without fusion
with env domain is shown in Fig. 3. As we reported
previously, these spherical particles had a diameter of
110–130 nm and were similar to that of mature HIV-1
particles budding from HIV-1 infected cells (Gelderblom
et al., 1987; Luo et al., 1990). The chimeric VLPs, gag–V3A
(Fig. 3B), gag–V3B (Fig. 3C), and gag–V3C (Fig. 3D),
appear to have similar morphology but slightly larger
than that of the gag particles without fusion with other
amino acids (Fig. 3A).
Antigenic characterization of V3 domain fused
in gag particles
To determine whether the three different gag–V3 fu-
sion particles can be recognized by the V3-specific sera,
raised against peptides of the V3 domain of HIV-1IIIB,
HIV-1MN, HIV-1RF, or HIV-1SF2, the antigenicity of the chi-
FIG. 2. Expression of chimeric gag–env proteins in SF21 cells infected by recombinant baculoviruses. Infected cells were harvested at 3 days p.i.
and whole cell lysates were analyzed by 12% SDS–PAGE stained with Coomassie blue (A) and detected by Western blot (B) using HIV positive patient
serum. Lanes 1–4: recombinant viruses AcNPV-HIV-2gag-, Ac–gag–V3A-, Ac–gag–V3B-, and Ac–gag–V3C-infected cells. The chimeric gag particles
purified from the culture supernatant were also subjected to SDS–PAGE and stained with Coomassie blue (C). M, marker protein; C, uninfected cell
control; Wt, wild-type BacPAK6-infected cells. The major fusion protein P53 is indicated with an arrow. The positions of molecular standard are given
in kDa.
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meric proteins was examined by pulse labeling the in-
fected cells with [35S]methionine for 1 h at 24 h p.i. and
immunoprecipitated with a panel of antisera and ana-
lyzed in SDS–PAGE. Figure 4 shows that the cell lysates
from SF21 cells infected with AcNPV-HIV-2gag (lane 1),
Ac–gag–V3A (lane 2), Ac–gag–V3B (lane 3), and Ac–gag–
FIG. 3. Electron micrograph of sucrose gradient-purified gag–env chimeric particles stained with uranyl acetate. (A) HIV-2 gag particles produced by SF21
cells infected with recombinant AcNPV-HIV-2gag virus as control. (B) Chimeric gag particles produced by recombinant Ac–gag–V3A. (C) Chimeric gag
particles produced by recombinant Ac–gagC–V3B. (D) Chimeric gag particles produced by recombinant Ac–gag–V3C. Bar represents 100 nm.
FIG. 4. Analysis of antigenicity of gag–V3 chimeric protein. SF21 cells were infected at m.o.i. of 5 PFU/cell with each recombinant baculoviruses
expressing the truncated gag or the gag–V3 chimeric proteins. After 24 h p.i. cells were pulse-labeled for 1 h with [35S]methionine. The cells infected
with recombinant viruses AcNPV-HIV-2gag, Ac–gag–V3A, Ac–gag–V3B, and Ac–gag–V3C were harvested separately and equal amounts were used
for immunoprecipitation with anti-V3IIIB monoclonal antibody (A), anti-V3MN antiserum (B), anti-V3RF antiserum (C), and anti-gp120SF2 antiserum (D). The
immunoprecipitated samples were analyzed in 12% SDS–PAGE and visualized by fluorography. Lane 1, recombinant viruses AcNPV-HIV-2gag; lane
2, Ac–gag–V3A; lane 3, Ac–gag–V3B; lane 4, Ac–gag–V3C-infected cells. The empty arrow indicates the chimeric protein size of Ac–gag–V3A.
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V3C (lane 4) were immunoprecipitated separately with
anti-V3IIIB monoclonal antibody (MAb) (Fig. 4A), anti-V3MN
MAb (Fig. 4B), anti-V3RF MAb (Fig. 4C), and anti-gp120SF2
from purified gp120SF2 (Fig. 4D). As expected, the HIV-2
gag protein expressed without env fusion by AcNPV-HIV-
2gag recombinant virus (Luo et al., 1990) was neither
recognized by antibodies against V3IIIB, V3MN, or V3RF
peptides nor by antibody against gp120SF2 (Figs. 4A, 4B,
4C, and 4D, lane 1). In contrast, the gag–V3A, gag–V3B,
and gag–V3C fusion proteins showed a strong reactivity
with their corresponding antisera against V3IIIB, V3MN,
V3RF or gp120SF2 (Fig. 4A, lane 2; 4B, lane 3; 4C and 4D,
lanes 4). The HIV-1IIIB V3-specific MAb showed a strong
reactivity only with gag–V3A and gag–V3C chimeric pro-
teins (Fig. 4A, lanes 2 and 4) which contained HIV-1IIIB V3
sequence, but barely binding with gag–V3B (Fig. 4A, lane
3). Although the gag–V3B contained three tandem copies
of consensus sequences of V3 domains of some 245
HIV-1 isolates, this sequence V3CS is closely related to
HIV-1MN strain and has 87% homology sequences with
V3MN (Fig. 1B). To determine the antigenicity of gag–V3B,
we employed the anti-V3MN antiserum to test whether it
recognizes the inserted V3CS sequence. As expected, the
anti-V3MN antibodies exhibited not only strong binding to
gag–V3B (Fig.4B, lane 3) but also to gag–V3A and gag–
V3C (Fig. 4B, lanes 2 and 4). In the same manner, both
the anti-V3RF and anti-gp120SF2 antibodies also recog-
nized gag–V3C, which contained V3IIIB, V3MN, V3RF, and
V3SF2 sequence, or bound to gag–V3A and gag–V3B
chimeric proteins (Figs. 4C and 4D). The monoclonal
antibody against V3 peptides of HIV-1IIIB strain reacted
only with V3IIIB. This result is consistent with previous
reports (Rusche et al., 1988; Javaherian et al., 1989).
These results clearly demonstrate that the chimeric pro-
teins can be detected by anti-V3 antibodies, which reaf-
firm the evidence that inserted sequences of multiple V3
epitopes are antigenic and indicate the cross-reactivity
between anti-V3MN, anti-V3RF, and anti-gp120SF2 antisera.
Immune responses to gag–env fusion VLPs
In order to examine whether the gag–env chimeric
particles are capable of inducing antibody response to
both gag and inserted peptides of env protein, each
group of four rabbits were immunized four times at
4-week intervals with purified gag–V3A, gag–V3B, or
gag–V3C chimeric particles as described under Materi-
als and Methods. The immune rabbit sera, obtained 2
weeks after the last boost immunization, and preimmune
sera were tested for their ability to recognize gag protein
and V3 peptides from gag–V3A, gag–V3B, and gag–V3C
anti-gag and anti-V3 antibodies levels were assessed by
ELISA. All rabbit groups generated a strong anti-gag
response (Table 1A), demonstrating that the chimeric
gag–V3 VLPs are potent immunogens. The gag–V3A,
gag–V3B, and gag–V3C VLPs induced anti-V3 responses
of 1:1000, 1:100, and 1:6400, respectively (Table 1B). This
value is relatively higher than the previously published
data (Truong et al., 1995). Consistent with these results,
approximately 1
10
dilution of antiserum was necessary to
inhibit 50% of homologous HIV-1 replication (data not
shown). Similar results have been reported by other
investigators. (Griffiths et al., 1993; Truong et al., 1995;
Wagner et al., 1996), suggesting that the weak neutraliz-
ing activity might be due either to an improper folding or
to limited accessibility of the inserted epitopes.
Induction of V3 peptide-specific CTLs with gag–V3C
chimeric particles
To test gag–V3C chimeric particles representing mul-
tiple V3 sequences from IIIB, MN, RF, and SF2 strains of
HIV-1 for induction of V3 peptide-specific CTL responses
in vivo, the Balb/C mice were immunized with 50 mg of
purified gag–V3C chimeric particles, spleens were re-
moved from primed mice at 5 weeks postimmunization,
and spleen cells were cultured. The pooled splenocytes
were divided into four aliquots and restimulated in vitro
with synthetic peptides of V3IIIB, V3MN, V3RF, or V3SF2. The
resulting effector cells were tested for their ability to lyse
the syngeneic target cells preincubated with cognate V3
peptides of IIIB, MN, RF, and SF2 strains of HIV-1. Figure
5 showed that the splenocytes from mice immunized
with gag–V3C particles resulted in specific CTL re-
sponses for all four V3 peptide-stimulated target cells,
but the CTLs induced by V3RF peptide exhibited a rela-
tively low level of specific lysis of target cells at an E:T
ratio of 5:1, 10:1, and 25:1. This result is consistent with a
previous report by Casement et al. (1995) that V3 peptide
from HIV-1RF is a weak inducer of CTLs. In contrast, V3
peptide-stimulated target cells were not lysed by effector
cells primed by synthetic peptides from LCMV nucleo-
TABLE 1A
Anti-gag Particle Responses
Antiserum Anti-gag
Anti-gag-
V3A
Anti-gag-
V3B
Anti-gag-
V3C
gag particles 2.17 1.09 0.98 1.52
Note. Data represent A415 values at 1:51,200 dilutions. Concentration
of gag particles: 100 ng/well.
TABLE 1B
Anti-V3 Immune Response Induced by Recombinant
Chimeric Particles
Chimeric particles
serum (dilutions) V3 peptides
Absorbance
(415 nm)
Anti-gag–V3A (1:1000) V3A 0.11
Anti-gag–V3B (1:100) V3B 0.12
Anti-gag–V3C (1:6400) V3C 0.21
Note. Concentration of V3 peptides: 100 ng/well.
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capsid protein (NP) and the LCMV NP peptide-stimulated
target cells were also not lysed by the effector cells
primed by V3C or V3B particles (data not shown). These
results indicated that the gag–V3 chimeric particle is
capable of inducing V3 peptide-specific CTL responses
in vivo.
Induction of cross-reactivity of CTLs by consensus V3
sequence
Previous reports have demonstrated that the V3 do-
main is one of the more variable regions of the envelope
glycoprotein and differs by as much as 50% in different
HIV-1 isolates (Myers 1989; Nara et al., 1988). For this
reason, We have expressed gag–V3B chimeric particles
which contain three tandem copies of consensus V3
sequence derived from 245 HIV-1 isolates, and tested
whether it could induce a broadly cross-reactive CTLs
against the variability of different isolates of HIV-1. As
expected, the splenocytes from mice immunized with
these purified chimeric gag–V3B particles developed a
broad CTL response after in vivo and in vitro restimula-
tion by V3IIIB peptides. Those splenocytes lysed the syn-
geneic target cells which were preincubated with indi-
vidual cognate V3IIIB, V3MN, V3RF, and V3SF2 peptides.
The cross-reactive lysis of P815 target cells in the range
of 40–52% at an E:T ratio of 25:1 was observed (Fig. 6).
This result is consistent with the previous report (Case-
ment et al., 1995) that the V3 peptides from HIV-1MN
strain appear to be more efficient than others, inducing a
broadly cross-reactive CTL response.
Characterization of the CTLs induced by gag–V3B
chimeric particles
Endogenously synthesized viral antigens are frag-
mented by antigen-processing enzymes in the cytoplasm
or endoplasmic reticulum and presented on the surfaces
of virus-infected cells in conjunction with class I major
histocompatibility complex (MHC) molecules. Such pro-
cessed peptides of viral proteins associated with class I
molecules can be recognized by CD81 CTLs that kill the
virus-infected cells. However, blocking of the antigen
presenting MHC molecule with a specific antibody would
inhibit target cell lysis. To determine whether the CTL
effector function in splenocytes from immunized mice
was due to CD81 or CD41 T cell, we treated the CTL
effectors, induced by immunizing the mice with gag–V3B
particles, with anti-CD8 or anti-CD4 antibody. The results
shown in Fig. 7 demonstrate that the anti-CD8 serum
treated CTL effectors abolished the cytotoxicity against
IIIB peptide-stimulated p815 target cells. In contrast, pre-
treatment of effector cells with anti-CD4 antibody had no
significant effect. Similar results were also obtained with
CTLs generated in mice immunized with gag–V3C parti-
cles. These results further demonstrate that the cytotoxic
response detected was mediated by class I-restricted
CD81 CTL.
FIG. 6. Analysis of cross-reactivity of CTLs induced by gag–V3B
purified chimeric particles. Balb/C mice were immunization and
boosted once (at day 7) with gag–V3B chimeric VLPs, which contain
three tandem copies of consensus V3 loop sequence (Fig. 1B), in
liposome emulsion (50 mg/100 ml/dose). The pooled splenocytes from
two mice per group were restimulated with V3IIIB peptide in vitro for 7
days, while the MHC-matched p815 target cells were pulsed with V3IIIB,
V3MN, V3RF, or V3SF2 peptides. CTL activity of splenocytes from the
immunized mice was measured at various effector and target cell ratios
(E:T) of 5:1, 10:1, and 25:1 in a standard of 6 h 51Cr release assay as
described under Materials and Methods. Specific lysis of target cells
are shown with nonspecific background lysis subtracted.
FIG. 5. Induction of CTLs in Balb/C mice by immunization with
purified gag–V3C chimeric particles. Balb/C mice were primed and
boosted once (at day 7) with V3C particles, corresponding to four
different V3 sequences from IIIB, MN, RF, and SF2 strains of HIV-1 (Fig.
1C) in liposome emulsion (50 mg/100 ml/dose). Spleen cells from two
mice per group were pooled and restimulated with V3IIIB, V3MN, V3RF, or
V3SF2 peptides in vitro for 7 days. CTL activity was measured using
MHC-matched p815 target cells, which were pretreated with V3IIIB,
V3MN, V3RF, or V3SF2 peptides, at effector to target cell ratios (E:T) of 5:1,
10:1, and 25:1 (see Materials and Methods). The cytotoxic response
was tested in a standard 6 h 51Cr-release assay. All levels of specific
lysis are shown, in which nonspecific background has been sub-
tracted.
321V3-SPECIFIC CYTOTOXIC T LYMPHOCYTE RESPONSES
DISCUSSION
In our present study we used truncated gag protein of
HIV-2 (Luo et al., 1990) to carry heterologous epitopes
representing V3 domain of gp120 from various strains of
HIV-1. In all three fusion constructs described in this
paper, we have attached multiple V3 sequences at the
C-terminus of the gag protein as shown in Fig. 1, which
has the capacity to code for 54 or 60 additional amino
acids, which is smaller in size than the deleted portion of
the gag gene (Luo et al., 1990). All three constructs
representing HIV-1 multiple V3 sequence were efficiently
packaged into VLPs that were morphologically similar to
virus-like gag particles without additional fusion se-
quences. This result is consistent with our previous re-
port that the C-terminus of HIV-2gag protein is not es-
sential for VLPs formation and further demonstrates that
by using the smaller size of heterologous proteins to
substitute the deleted C-terminal portion of gag renders
assembly and release of the chimeric fusion protein
particles (Luo et al., 1992).
In this report, we present the cytotoxic T cell induction
by three intramuscular immunizations using gag–V3
VLPs entrapped in liposome. The V3 domain specific
CTL response with broad reactivity patterns can be elic-
ited by three tandem copies of consensus V3 peptide
(gag–V3B) or multideterminant clusters of V3 peptide
(gag–V3C) immunization. Our results show that the
gag–V3 particles induced cytotoxic T-cell responses to a
broad spectrum of HIV-1 clade B isolates. This is con-
sistent with the report by Casement et al., (1995) that the
V3 peptide from MN strain of HIV-1 induced CTLs that
exhibited cross-reactivity against a broad range of HIV-1
strains and suggests that the foreign CTL epitopes are
efficiently presented by the chimeric gag–V3 VLPs. In
whole, the consensus V3 domain sequence efficiently
elicited a broadly cross-reactive CTL response that cov-
ers the clade B of HIV-1 which represents most North
American isolates. Very recently it has been demon-
strated that clade B-based canarypox vaccines can elicit
broad CTL reactivities capable of recognizing viruses
belonging to genetically diverse HIV-1 clades (Ferrari et
al., 1997).
Although the molecular mechanism of CTL induction is
not clear, the fact that gag–V3B and gag–V3C induce
class I-restricted T cell reflect that the CTL epitope pre-
sented by chimeric particles is able to enter the antigen
processing pathway that leads to the association with
class I MHC molecules. Therefore, the incorporation of
multiple V3 sequences into gag particles is an efficient
method for the presentation of exogenous antigens and
induction of a dominant CTL response. The entry of
exogenous protein to the endogenous class I processing
pathway has been reported in some viral polypeptides
(Ahlers et al., 1996; Sauzet et al., 1995; Zamorano et al.,
1994; Hsu et al., 1995) and particulate structures such as
yeast-derived Ty virus-like particle (Layton et al., 1996),
chimeric HIV-1 virus like particles (Wagner et al., 1996),
hepatitis B virus surface antigen particles (Schirmbeck et
al., 1994), and biodegradable microparticles as a delivery
for measles viruse CTL epitopes (Partidos et al., 1996).
The exogenous viral proteins and virus-like particles are
processed for CTL induction have also been proven in
dendritic cells (Bachmann et al., 1996). A few years ago,
Hilleman (1995) compared the immunology and patho-
genesis of AIDS, hepatitis B, and measles for developing
a HIV vaccine and indicated that it was a failure in the
past to emphasize the use of gag gene-encoded anti-
gens in vaccines that may be more conserved antigeni-
cally and critical to protective CTL responses, as in
hepatitis B. Virus-like particles as vaccine candidates
offer the advantage of being a safe and economic com-
parison to inactivated or attenuated whole viruses. The
noninfectious VLPs carrying the considered antigenic
domain could be expressed in large quantities and is
easy for purification. This system allows the selective
expression of a defined region of HIV protein in an
immunoprominent epitope and therefore enables a spe-
cific immune response to be induced. The ability of
fusing a large epitopes onto a noninfectious gag parti-
cles opens up another way of designing vaccines
against HIV infection.
MATERIALS AND METHODS
Plasmid construction
To construct hybrid gag–multiple V3 genes, the plas-
mid pUC19 containing the HIV2-gag425 gene was em-
ployed as a carrier as previously described (Luo et al.,
1992). Synthetic multiple V3 loop sequences were in-
serted into the BglII site located at the C terminus of gag
FIG. 7. The CD81 T cell subpopulation was responsible for the
cytotoxic activity. The CTLs induced by immunization with gag–V3B
chimeric particles containing three tandem copies of consensus V3
loop sequence were depleted mostly by preincubation with anti-CD8
antibody, but not with anti-CD4 antibody. The MHC-matched p815 target
cells were stimulated with V3IIIB peptides. The ratio of the effector to
target cell (E:T) are indicated on the bottom. The percentage of specific
lysis is shown after subtracting the background lysis of control.
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gene to extend the gag reading frame and resulted in the
generation of chimeric gag–V3 genes. Figure 1 shows
the three constructs of the plasmids used in this study
and indicates the inserted env gene sequences. All in-
serted sequences were confirmed by dideoxy DNA se-
quencing of the double-stranded DNA, using the Seque-
nase kit (United States Biochemical Corp).
Production of recombinant baculovirus
The generation of recombinant baculovirus was car-
ried out by cotransfecting SF21 cells with linearized wild
type BacPAK6 viral DNA and transfer vector pBacPAK1
DNA by using liposome-mediated gene transfer with
lipofectin technique provided in the BacPAK baculovirus
expression system kit (Clontech Laboratories, Inc.) ac-
cording to the manufacturer’s instruction. A few viral
plaques were picked and recombinant viruses were ver-
ified by Western blot ((Luo et al., 1992). The newly iso-
lated recombinant virus was purified by further consec-
utive plaque assay and used to produce a virus stock of
2 3 108 PFU/ml.
Purification of chimeric gag particles
SF21 cells were infected with recombinant baculovirus
at a multiplicity of infection of 5 PFU/cell and incubated
at 27°C for 72 h. The cell culture supernatant was col-
lected after centrifugation at 1000 g for 20 min. Sediment-
able particles in the culture supernatant were collected
by ultracentrifugation at 80,000 g for 1 h using a SW 28
rotor and resuspended in PBS containing 0.1% Tween 20
and 10 mg/ml aprotinin. The chimeric gag particle band
was collected from a 20–60% step sucrose gradient after
centrifugation at 100,000 g for 4 h in a SW41 rotor and
diluted at least 10-fold with PBS and repelleted by cen-
trifugation at 80,000 g for 1 h in a SW28 rotor (Luo et al.,
1992, 1994). The pellet was gently resuspended in phos-
phate-buffered saline (PBS) and used for further analy-
ses including electron microscopy.
Transmission electron microscopy
The electron microscopy was carried out as described
previously (Luo et al., 1994). Briefly, the samples were
placed onto a carbon grid and then stained with 1%
uranyl acetate and examined in a Philip 300 transmission
electron microscope.
Protein expression and immunoprecipitation
SF21 cells were infected with either wild type BacPAK6
or recombinant baculovirus at a multiplicity of infection of
5 PFU/cell and incubated at 27°C. After appropriate in-
cubation time, cells were harvested and washed twice
with PBS. Whole cell lysates were prepared by resus-
pending the cell pellets in water and adding an equal
volume of 23 dissociation buffer (10% b-mercaptoetha-
nol, 10% sodium dodeayl sulfate (SDS), 25% glycerol, 100
mM Tris–HCl, pH 6.8, and 0.04% bromophenol blue). Cell
lysates were analyzed in 12% SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) and the protein bands were
visualized by staining with Coomassie blue and con-
firmed by using ECLTM Western blotting kit (Amersham
Life Science). For the analysis of antigenicity of chimeric
VLPs, pulse-labeling of infected SF21 cells was carried
out as previously described (Li et al., 1993, 1994). Briefly,
at 24 h (p.i.), the infected SF21 cells were incubated in
methionine-free Grace’s medium for 30 min and pulse-
labeled for 1 h using [35S]methionine (250 mCi/ml). Cells
were lysed in an extraction buffer (50 mM Tris–HCl, pH
8.0, 1% NP40, 150 mM NaCl, and 1 mM phenylmethyl-
sulfonyl fluoride). Anti-V3 antiserum was added to the
clarified cell lysate and incubated at 4°C for 12 h. Im-
mune complexes were recovered with protein A–Sepha-
rose CL-4B beads and washed three times with RIPA
buffer (50 mM Tris–HCl, pH 8.0, 1% NP40, 150 mM NaCl,
1% deoxycholate, 0.1% SDS, and 1 mM EDTA). Protein
samples were analyzed by 12% SDS–PAGE and visual-
ized by fluorography.
Generation and measurement of antiserum to
chimeric gag–env fusion protein
Purified gag–V3 chimeric particles containing multiple
neutralizing and CTL epitopes of HIV-1 were used to
generate antiserum. Six New Zealand white rabbits were
immunized with 30 mg of purified chimeric gag–V3 par-
ticles by four intramuscular injections at 1-month inter-
vals. The immunogens were formulated with complete
Freund’s adjuvant for primary injection and with incom-
plete Freund’s adjuvant for boosting at 1:1 ratio. Serum
samples were taken before the injections and 2 weeks
after each injection.
The anti-V3 and anti-gag responses were evaluated in
a solid-phase enzyme-linked immunosorbent assay
(ELISA) by using the gag–V3A, gag–V3B, and gag–V3C-
related synthetic V3 domain peptides (see Fig. 1), the
purified chimeric gag–V3, or the gag particles. All sam-
ples in carbonate–bicarbonate, pH 9.6, were coated on
microtiter plates (Microtest III flexible assay plate, Bec-
ton Dickinson, Oxnard, CA) at a concentration of 100
ng/well at 37°C overnight. After the plates were washed
three times with PBS containing 0.5% Tween 20, the
wells were blocked with 5% nonfat dry milk powder
dissolved in PBS at 37°C for 1 h. After washing three
more times, the plates were incubated with a serial
twofold dilution of the various antisera at 37°C for 1 h
and processed with the respective secondary antibodies
conjugate to horseradish peroxidase diluted in 1:3000
(Bio-Rad) for another hour at 37°C. The microtitre plates
were washed five times between incubations, the un-
bounded conjugate was removed and the bounded en-
zyme was detected by the addition of 100 ml of a 2,20-
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azino bis[3-ethylbenzthiazolin-6-sulfonic acid] and H2O2
solution, a commercially available kit (Peroxidase Sub-
strate Kit, Bio-Rad, Hercules, CA), according to the man-
ufacturer’s instructions. After 10 min of color develop-
ment, the absorbance was read in a Bio-Rad Model 550
microplate reader at 415 nm. Virus neutralization assay
was carried out as described previously (Luo et al., 1992;
Wagner et al., 1996).
Preparation of liposomes
Multilamellar vesicles (MLV) were prepared by vortex-
ing. Lipids (phosphatidylethanolamine-b-oleoyl-a-palmi-
toyl:cholesteryl hemisuccinate 5 7:3 mole ratio) were
dissolved in 1 ml chloroform and dried under a stream of
nitrogen gas to form a thin film on the wall of a glass
tube. A PBS buffer solution containing protein antigen
(gag–V3B and gag–V3C) was introduced into the glass
vial and vortexed vigorously. Freezing–thawing vesicles
(FTV) were prepared as described by Zhou et al. (1991).
Briefly, small unilamellar vesicles (SUV) were produced
by sonicating MLV and further incubated at room tem-
perature for 1 h. After that, the SUV was briefly sonicated
and then rapidly frozen in liquid nitrogen and slowly
thawed at room temperature. The freezing–thawing pro-
cess was repeated for a total of four times.
Cytotoxic T-lymphocyte assay
Female Balb/C mice (5–6 weeks old) were immunized
by intramuscular injection with either 50 mg of gag–V3C
or gag–V3B chimeric particles in a 1:20 (protein:lipid)
ratio with liposome entrapped. The boosting was per-
formed at day 7 after the first immunization by the same
route. The spleens were removed from immunized mice
4 weeks after the final immunization, and spleen-cell
suspensions were prepared and pooled from two mice
per group. The pooled cells were divided into four ali-
quots and restimulated in vitro for 7 days with individual
V3 peptides (4 mg/ml) representing four HIV-1 isolates:
V3IIIB (RIQRGPGRAFVTIGK), V3MN (HIGPGRAFYTTKN),
V3RF (TKGPGRVIYATGQ), and V3SF2 (YIGPGRAFHTTGR).
For preparation of peptide-stimulated target cells p815 [a
MHC-matched (H-2d) mastocytoma cell line], the p815
cells (1 3 106/ml) were preincubated individually with 20
mg of V3 peptides representing IIIB, MN, RF, or SF2
strains of HIV-1 clade B for 16–17 h and labeled with 51Cr
for another 2 h at 37°C. Control target cells were incu-
bated with either medium alone or with a oligopeptides
representing lymphocytic choriomeningitis virus (LCMV)
nucleocapsid protein NP, 119–127: (PQASGVYMG).
The CTL activity against peptide-stimulated target
cells was determined in a standard 6-h 51Cr-release
assay. Aliquots of 5 3 105, 2 3 105, and 1 3 105 effector
cells per well were mixed with 2 3 104 51Cr-labeled
target cells for 6 h in 96-well microtiter plates, and then
100 ml of supernatant was collected for 51Cr-release
assay. The percentage-specific 51Cr-release was calcu-
lated as 100 3 (sample release 2 spontaneous release)/
(maximum release 2 spontaneous release). Spontane-
ous release was determined from target cells incubated
with culture medium and was less than 15% in all exper-
iments. The maximum release was determined from tar-
get cells lysed by 2% Triton X-100. Each E/T ratio was
tested in triplicate and repeated at least twice.
Depletion of CD41 or CD81 cells
CD41 cell- or CD81 cell-depleted populations were
obtained by incubating restimulated splenocytes with
anti-CD4 or anti-CD8 monoclonal antibodies, respec-
tively. Resulting cells were then tested for their capacity
to lyse MHC-matched p815 target cells that were pre-
treated with V3IIIB peptide. In this experiment, CTL effec-
tors and target cells were mixed at various E:T ratios of
25:1, 10:1, and 5:1. The culture supernatant of 51Cr-labeled
cells were harvested and determined by 51Cr release
assay.
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